Drug discovery link-up for Galapagos and NovAliX
Collaboration comes after renewed focus on key therapeutic areas of immunology and oncology
Read More
Tag: Galapagos
Galapagos reports early clinical results for SIK inhibitor
Novel drug candidate found to be generally safe and well-tolerated in inflammatory indications
Read More
Galapagos’ filgotinib leads to rapid symptom improvement for ulcerative colitis patients
Data also suggested filgotinib 200mg reduced and eliminated corticosteroid use compared to placebo
Read More
EMA begins evaluation of filgotinib for ulcerative colitis
Gilead and Galapagos’ application for oral JAK1 inhibitor validated by agency
Read More
Gilead’s oral JAK inhibitor filgotinib wins EU approval
Treatment is indicated for use in adults with moderate-to-severe active rheumatoid arthritis
Read More
Galapagos signs deal with Scipher for IBD drug development
Companies will jointly validate novel IBD targets
Read More
Gilead, Galapagos form $5.1b R&D partnership
Galapagos will receive a $3.95 billion upfront payment and a $1.1 billion equity investment from Gilead, which it will use to expand and accelerate its research and development programs.
Read More
Gilead, Galapagos’ filgotinib hits goals in RA trial
Gilead and Galapagos have unveiled another set of promising data for JAK inhibitor filgotinib, this time in rheumatoid arthritis.
Read More
Gilead, Galapagos’ filgotinib succeeds in PhII ankylosing spondylitis trial
A mid-stage trial assessing Gilead and Galapagos’ JAK 1 inhibitor filgotinib in ankylosing spondylitis has hit its targets.
Read More
Novartis bags rights to Galapagos/MorphoSys atopic dermatitis drug
Novartis has signed an exclusive global license agreement with Galapagos and MorphoSys for MOR106, a novel antibody directed against IL-17C.
Read More
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
